Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free: https://www.ghostery.com/fr/products/

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site: http://www.youronlinechoices.com/fr/controler-ses-cookies/, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Realytics
Google Analytics
Spoteffects
Optimizely

Targeted advertising cookies

DoubleClick
Mediarithmics

The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at cil-dpo@inra.fr or by post at:

INRA
24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu Logo Principal logo Université Clermont Auvergne & associés

Human Nutrition Unit

Zone de texte éditable et éditée et rééditée

Dr Isabelle PAPET

Research activities

Dr Isabelle PAPET

PAPET Isabelle

Email : contact
Tel : +33(0)4 73 62 42 01

The number of older people is growing and it will continue to increase in the future. Aging is associated with the alteration of many physiological functions and the increase of medication use. Sarcopenia, which is the loss of muscle mass associated with aging, is a major component of frailty. Frail older persons are at high risk of entering into functional disability and irreversible dependency. The objective of our work is to limit sarcopenia with a more adequate diet in order to promote the independence of the elderly as long as possible. It is of primarily importance to better understand the metabolic alterations involved in the development of sarcopenia. Aside from the reduction in physical activity, inflammation and oxidative stress are determining factors in the processes involved in sarcopenia. These factors have been the subject of numerous studies within our research unit and externally. Our originality is to presently study the role that poly-medication that is also an important component of frailty may, or not, play in the development of sarcopenia. Among the various potential interactions between medications and sarcopenia, we are interested in metabolic interactions with amino acids that can modify the homeostasis of muscle protein. As an example, we are studying the potential pro-sarcopenic effect of cures with paracetamol, an analgesic that is very widely used by the elderly to relieve pain of low to moderate intensity.

Activités de recherche

 Activité de recherche       Publications       Parcours et Éléments de CV

Inflammation and sarcopenia
Inflammation is a complex response to various conditions ranging from increased body fat mass to severe injuries/pathologies. During aging, systemic inflammation can be revealed by the increase of acute phase proteins. Within a cohort of aging rats, some do not show any systemic inflammation (ie, acute phase proteins not higher than in adult rats), others exhibit low-grade inflammation, whereas acute inflammation may be associated with some pathological status. We compared low-grade inflamed with non-inflamed old rats. Whether or not these rats are under stress (nutritional or inflammatory), the pre-existing low-grade inflammation has no effect on the mass of leg muscles. For sure, acute inflammation induced by an infection strongly reduces muscle masses. Usually, acute muscle loss is not efficiently recovered in elderly. Thus, the contribution of acute inflammation to the development of sarcopenia is likely much larger than that of low-grade inflammation. The threshold above which inflammation is detrimental for skeletal muscle remains to be determined.

Potential pro-sarcopenic effect of paracetamol
The detoxification of paracetamol through sulfation and the mercapturate pathway induce a net loss of cysteine. We hypothesized that this phenomenon could occur at the expense of the other metabolic uses of cysteine, notably for skeletal muscle protein turnover. We performed several studies in adult and old rats showing that chronic treatment or repeated cures with paracetamol can reduce muscle mass. Our results suggest that the need of cysteine ​​may be uncovered in elderly people who are frequently treated with paracetamol, especially in those with low food intakes.

back

Isabelle Papet Publications

Read more